PerkinElmer has opened a second specialized Good Manufacturing Practice (GMP) services facility. The Company has claimed that it has launched this capability in response to increasing demand for custom radiosynthesis of potential drug compounds for ADME (Absorption, Distribution, Metabolism and Excretion) research studies.
Reportedly, PerkinElmer’s GMP Radiosynthesis Services provide expertise for the manufacture and synthesis of radiolabeled compounds to help pharmaceutical, biotechnology and contract research organizations (CROs) accelerate drug development.
It has been reported that PerkinElmer had inaugurated its first GMP compliant facility in late 2008 in Boston, and has now doubled its capacity for GMP based services, due to increased client uptake throughout 2009.
Richard Eglen, president of bio-discovery at PerkinElmer, said: PerkinElmer is pleased to announce this expansion of our GMP facilities to better serve our clients, through advanced services designed to improve and enhance studies of potential drug compounds. Radiolabeling of new drug candidates for ADME is a major tool that assists drug discovery researchers to better understand the distribution of the compound as it moves through the body.
With the cost of drug development remaining high, and the costs of potential failures further down the research pipeline growing, PerkinElmer is responding to increased pharma demand for stronger early indicators of potential success or failure to make better decisions regarding project advancement, he added.